“Revolutionizing Spinal Cord Injury Treatment: Tiziana Life Sciences’ Nasal Anti-CD3 Shows Promising Results”
Tiziana Life Sciences Announces Breakthrough Study Results in Traumatic Spinal Cord Injury New York, Jan. 23, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced results from studies…